Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab Services
15 Junho 2023 - 9:00AM
Daxor Corporation
(Nasdaq: DXR), the global leader in blood volume
measurement technology, today announces the launch of a new service
designed to drive faster adoption and provide greater prescriber
access to Daxor’s innovative blood volume analysis technology
(BVA).
Daxor’s ezBVA Lab is a state-of-the-art CLIA
certified facility located at Daxor’s Oak Ridge facility that
provides on-demand, next day blood volume analysis results. The lab
is staffed by certified nuclear medicine technologists overseen by
a board-certified medical director.
“This service allows customers at licensed
hospitals and clinics to send patient blood samples to Daxor for
24-hour processing, lowering the labor, and the overhead required
to conduct the test and deliver results. We anticipate a quicker
customer launch and shorter sales cycle at new accounts as a result
of this streamlined process,” said Jean Oertel, Senior VP of
Commercialization.
“Daxor’s ezBVA Lab requires no capital
investment from our customers while easily integrating into
workflow with eligible reimbursement by both private and public
insurance,” said Michael Feldschuh, CEO of Daxor Corporation. “We
are excited to provide a simpler, cost-effective solution for
hospitals and clinicians to adopt our technology who do not have
our analyzer systems available in their lab but will instead
utilize Daxor’s paid lab service, so providers can achieve optimal
fluid management for their patients.”
About Daxor
Corporation
Daxor Corporation (Nasdaq: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the first diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. Over 65,000+ tests have been performed at leading hospital
centers across the U.S., enhancing hospital performance metrics in
a broad range of surgical and medical conditions, including
significantly reducing mortality and readmissions in heart failure
and critical care. Daxor has several ongoing multicenter trials in
the areas of COVID-19 and heart failure treatment with support from
the NIH and is under contract developing analyzers to improve
combat casualty care with the U.S. Department of Defense. Daxor's
mission is to advance healthcare by enabling optimal fluid
management with blood volume analysis. Daxor’s vision is optimal
blood volume for all. For more information, please visit our
website at Daxor.com. Sign up to receive news on
Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr.
Managing Partner, CORE IR516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Daxor (NASDAQ:DXR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024